识别失代偿高风险代偿期肝硬化患者模型的验证
研究基于英国诺丁汉145例代偿期肝硬化患者队列(中位随访4.59年)开发联合ALBI与FIB-4评分的模型,用于识别失代偿高风险患者,并在爱尔兰和埃及两个外部队列共234例患者中验证。开发队列中19.3%发生失代偿,高风险评分患者失代偿风险比(HR)为7.10,验证队列中爱尔兰为12.54、埃及为5.10。
要点
- 联合ALBI与FIB-4评分可识别代偿期肝硬化中失代偿高风险患者。
- 开发队列高风险评分患者失代偿HR为7.10。
- 外部验证队列高风险评分患者失代偿HR分别为12.54和5.10。
核心结论
- 基于ALBI与FIB-4评分组合的评分系统可识别有肝失代偿风险的患者。
- 该评分系统在两个独立国际队列(欧洲和中东)中得到验证,似乎适用于不同人群。
研究设计与样本
- 开发队列为英国诺丁汉的145例代偿期肝硬化患者(91%为Child A级肝硬化,中位MELD评分低于8),中位随访4.59年。
- 收集基线临床特征并记录失代偿事件,基于ALBI评分评估的肝功能和FIB-4指数评估的纤维化程度开发失代偿风险模型。
- 在2个独立外部队列(爱尔兰都柏林和埃及梅努菲亚)共234例患者中验证模型。
主要发现
- 开发队列中19.3%的患者发生失代偿期肝硬化。
- 开发队列中高风险评分患者失代偿的风险比(HR)为7.10。
- 验证队列中高风险评分患者失代偿的HR在爱尔兰队列为12.54,在埃及队列为5.10。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It is important to rapidly identify patients with advanced liver disease. Routine tests to assess liver function and fibrosis provide data that can be used to determine patients' prognoses. We tested the validated the ability of combined data from the ALBI and FIB-4 scoring systems to identify patients with compensated cirrhosis at highest risk for decompensation. METHODS: We collected data from 145 patients with compensated cirrhosis (91% Child A cirrhosis and median MELD scores below 8) from a cohort in Nottingham, United Kingdom, followed for a median 4.59 years (development cohort). We collected baseline clinical features and recorded decompensation events. We used these data to develop a model based on liver function (assessed by the ALBI score) and extent of fibrosis (assessed by the FIB-4 index) to determine risk of decompensation. We validated the model in 2 independent external cohorts (1 in Dublin, Ireland and 1 in Menoufia, Egypt) comprising 234 patients. RESULTS: In the development cohort, 19.3% of the patients developed decompensated cirrhosis. Using a combination of ALBI and FIB-4 scores, we developed a model that identified patients at low vs high risk of decompensation (hazard ratio [HR] for decompensation in patients with high risk score was 7.10). When we tested the scoring system in the validation cohorts, the HR for decompensation in patients with a high-risk score was 12.54 in the Ireland cohort and 5.10 in the Egypt cohort. CONCLUSION: We developed scoring system, based on a combination of ALBI and FIB-4 scores, that identifies patients at risk for liver decompensation. We validated the scoring system in 2 independent international cohorts (Europe and the Middle East), so it appears to apply to diverse populations.
引用
- Guha IN, Harris R, Berhane S, et al. Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation. Clin Gastroenterol Hepatol. 2019. PMID: 30716478. doi:10.1016/j.cgh.2019.01.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。